CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Previous Infection and Effectiveness of COVID-19 Vaccination in Middle- and High-School Students
-
12 01 2023
-
Source: Pediatrics. 152(6)
Details:
-
Alternative Title:Pediatrics
-
Personal Author:
-
Description:BACKGROUND AND OBJECTIVES:
Understanding the real-world impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mitigation measures, particularly vaccination, in children and adolescents in congregate settings remains important. We evaluated protection against SARS-CoV-2 infection using school-based testing data.
METHODS:
Using data from Utah middle- and high-school students participating in school-wide antigen testing in January 2022 during omicron (BA.1) variant predominance, log binomial models were fit to estimate the protection of previous SARS-CoV-2 infection and coronavirus disease 2019 vaccination against SARS-CoV-2 infection.
RESULTS:
Among 17910 students, median age was 16 years (range: 12–19), 16.7% had documented previous SARS-CoV-2 infection; 55.6% received 2 vaccine doses with 211 median days since the second dose; and 8.6% of students aged 16 to 19 years received 3 vaccine doses with 21 median days since the third dose. Protection from previous infection alone was 35.9% (95% confidence interval [CI]: 12.9%–52.8%) and 23.8% (95% CI: 2.1%–40.7%) for students aged 12 to 15 and 16 to 19 years, respectively. Protection from 2-dose hybrid immunity (previous SARS-CoV-2 infection and vaccination) with <180 days since the second dose was 58.7% (95% CI: 33.2%–74.4%) for students aged 12 to 15 and 54.7% (95% CI: 31.0%–70.3%) for students aged 16 to 19 years. Protection was highest (70.0%, 95% CI: 42.3%–84.5%) among students with 3-dose hybrid immunity, although confidence intervals overlap with 2-dose vaccination.
CONCLUSIONS:
The estimated protection against infection was strongest for those with hybrid immunity from previous infection and recent vaccination with a third dose.
-
Subjects:
-
Source:
-
Pubmed ID:37960897
-
Pubmed Central ID:PMC11247457
-
Document Type:
-
Funding:
-
Volume:152
-
Issue:6
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-508.10 KB]
